Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rifampicin 600 mg Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rifampin and the Contraceptive Implant

NCT04463680
View directory record Official record
Conditions
Contraception, Tuberculosis
Interventions
Rifampin 600 MG
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

NCT02430545
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glasdegib, Rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rifampin Drug-Drug Interaction Study With Lurasidone HCl

NCT01082276
View directory record Official record
Conditions
Male, Healthy Normal Subjects
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Results available

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

NCT04537715
View directory record Official record
Conditions
All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor
Interventions
Tazemetostat, Itraconazole, Rifampin
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Encinitas, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

NCT00096850
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Atazanavir, Rifampin, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
3
States / cities
Palo Alto, California • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

NCT01765543
View directory record Official record
Conditions
Malignant Melanoma, Neoplasms
Interventions
Rifampin, Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Rogers, Arkansas • Pleasant Hill, California • Middletown, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

NCT03296800
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Probenecid, Rifampin, Verapamil
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

NCT03928327
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-788, Itraconazole, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 24, 2026, 5:48 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants

NCT04558216
View directory record Official record
Conditions
Healthy Participants
Interventions
Vonoprazan, Rifampin
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin on the Pharmacokinetics of BAY73-4506

NCT01322438
View directory record Official record
Conditions
Neoplasms
Interventions
Regorafenib (BAY73-4506) + rifampin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

NCT00405080
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
GW679769 (Casopitant) oral tablets, Rifampin oral capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast

NCT01561963
View directory record Official record
Conditions
Healthy Subjects
Interventions
Apremilast, Rifampin Oral Capsules, Rifampin IV Solution
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

NCT03712540
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986278, Rifampin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis

NCT00108862
View directory record Official record
Conditions
HIV Infection, Tuberculosis
Interventions
Strategy: Immediate ART, Strategy: Deferred ART
Other
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Between Rifampin and Fluvastatin

NCT04029584
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
rifampin IV, Rifadin 300Mg Capsule, Fluvastatin 20 MG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

NCT05720767
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
HMPL-523, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 24, 2026, 5:48 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

NCT01068756
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Rifampin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VX-770 and Rifampin in Healthy Male Subjects

NCT01018368
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770, Rifampin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2010 · Synced Sep 24, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT04553406
View directory record Official record
Conditions
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions
SPR720, Placebo, Open-label Standard of Care
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion

NCT02085967
View directory record Official record
Conditions
Healthy Subjects
Interventions
rifampin 600 mg, itraconazole 200 mg, midazolam 2 mg with bupropion 75 mg, E2006
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants

NCT01763021
View directory record Official record
Conditions
Healthy Participants
Interventions
PCI-32765, Rifampin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

NCT02807116
View directory record Official record
Conditions
Healthy Subjects
Interventions
Pacritinib, Rifampin, Pacritinib and Rifampin
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 2Phase 3 Interventional

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

NCT03672630
View directory record Official record
Conditions
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
Interventions
Azithromycin, Ethambutol, Rifampin
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
25
States / cities
Loma Linda, California • San Diego, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 24, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines

NCT05592223
View directory record Official record
Conditions
Tuberculosis
Interventions
BCG Vaccine USP, Isoniazid, Rifampin
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 24, 2026, 5:48 PM EDT